What Happened

Serapha Bio launched on June 23, 2026, with $230M in total funding. The startup combined a $138M Series A led by RA Capital and RTW Investments with a $92M reverse merger with cancer-focused Boundless Bio.

Who Is Affected

Serapha Bio's leadership team and investors (RA Capital, RTW) are now capitalizing on gene-editing for Alpha-1 Antitrypsin Deficiency. Boundless Bio's assets and team are integrated post-merger. Chinese pharma partners are undisclosed but actively engaged.

Market Impact

• Validates gene-editing for rare diseases (AATD affects ~100k globally)
• Signals investor confidence despite Boundless Bio's prior clinical setbacks
• Chinese partnership indicates international commercialization strategy

What to Watch

Serapha's preclinical progress for AATD therapy and additional partnerships. RA Capital's involvement suggests aggressive timeline—typical 18-24 months to IND.